NASDAQ:AMGN Amgen Q3 2026 Earnings Date & Estimates $463.02 -2.99 (-0.64%) As of 10:23 AM Eastern This is a fair market value price provided by Massive. Learn more. Amgen is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 3, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Amgen in Q3 2026Amgen is expected to post earnings of $5.79 per share on revenue of $10.07 billion. In the same quarter a year earlier Amgen reported $5.64 per share on revenue of $9.56 billion. Amgen last reported on August 4, 2026, posting $6.29 per share and beating the $5.62 consensus estimate. Amgen has beaten the consensus EPS estimate in 8 of its last 8 quarters.Consensus EstimatesConsensus EPS$5.79Expected Revenue$10.07 billionPrior-Year EPS$5.64Prior-Year Revenue$9.56 billionExpected EPS Growth+2.7%Expected Revenue Growth+5.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS$6.29 (Beat by +$0.67)Last Quarter Revenue$10.05 billionEPS Beat Rate8 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Amgen Q3 2026 Earnings FAQ When does Amgen report Q3 2026 earnings? Amgen (NASDAQ:AMGN) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Amgen's Q3 2026 earnings call? Amgen's Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Amgen? Analysts expect Amgen to post earnings of $5.79 per share for Q3 2026. How much revenue is Amgen expected to report? The consensus revenue estimate for Amgen is $10.07 billion for Q3 2026. Amgen Earnings HeadlinesAmgen (AMGN) reports Q3: everything you need to know ahead of earnings3 hours ago | finance.yahoo.comAmgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey NarrativeOctober 31 at 11:32 PM | finance.yahoo.comGovernment Document Reveals Plan To Control Your Money (it will disturb you)A Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.November 2 at 1:00 AM | Weiss Ratings (Ad)Looking For Growth, Income, and Stability? This Stock Could Offer All 3October 31 at 6:31 PM | fool.comLooking For Growth, Income, and Stability? This Stock Could Offer All 3 October 31 at 1:31 PM | fool.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN), HCA Healthcare (HCA) and Teladoc (TDOC)October 31 at 2:59 AM | theglobeandmail.comSee More Amgen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amgen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amgen and other key companies, straight to your email. Email Address About AmgenAmgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers. Founded in 1980, Amgen is headquartered in Thousand Oaks, California. The company serves patients and healthcare providers in the United States and international markets through its research, manufacturing and commercial operations. Amgen is led by Chairman and Chief Executive Officer Robert A. Bradway.View Amgen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall?LyondellBasell's Dividend Looks Safer, But a New Risk Could Change ThatUranium Prices Are Near Historic Highs—So Why Hasn’t Cameco Followed?Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead Upcoming Earnings Booking (11/3/2026)Ferrari (11/3/2026)Marathon Petroleum (11/3/2026)Mplx (11/3/2026)Suncor Energy (11/3/2026)Apollo Global Management (11/3/2026)Itau Unibanco (11/3/2026)Amgen (11/3/2026)Pfizer (11/3/2026)Eaton (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
